Compare VITL & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VITL | OPK |
|---|---|---|
| Founded | 2007 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 944.3M | 921.2M |
| IPO Year | 2020 | 2011 |
| Metric | VITL | OPK |
|---|---|---|
| Price | $17.24 | $1.18 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $42.56 | $2.03 |
| AVG Volume (30 Days) | ★ 2.2M | 2.0M |
| Earning Date | 06-01-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.03 | N/A |
| EPS | ★ 1.44 | N/A |
| Revenue | ★ $759,444,000.00 | $606,879,000.00 |
| Revenue This Year | $22.76 | N/A |
| Revenue Next Year | $18.53 | $4.76 |
| P/E Ratio | $12.14 | ★ N/A |
| Revenue Growth | ★ 25.26 | N/A |
| 52 Week Low | $17.35 | $1.11 |
| 52 Week High | $53.13 | $1.87 |
| Indicator | VITL | OPK |
|---|---|---|
| Relative Strength Index (RSI) | 17.08 | 43.32 |
| Support Level | N/A | $1.12 |
| Resistance Level | $31.02 | $1.27 |
| Average True Range (ATR) | 1.09 | 0.05 |
| MACD | -0.37 | 0.00 |
| Stochastic Oscillator | 3.06 | 34.62 |
Vital Farms Inc is an ethical food company. The company retails pasture-raised eggs and butter. Its products include Pasture-Raised Eggs and Pasture-Raised Butter & Ghee. The company's purpose is rooted in a commitment to Conscious Capitalism, which prioritizes the long-term benefits of its stakeholders (farmers and suppliers, customers and consumers, communities and the environment, employees, and stockholders).
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.